US EditionPublished • loading... • Updated
Orthocell records first sales of flagship nerve repair product Remplir in Canada
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Orthocell records first sales of flagship nerve repair product Remplir in Canada
Orthocell reports first commercial sales of Remplir in Canada following regulatory approval and 2025 launch activities Distributor-led model supports national coverage and capital-light entry into ~US$75m Canadian market Remplir now generating revenue across multiple markets as global rollout continues Special Report: Orthocell has reported first commercial sales of Remplir in Canada, marking a key milestone in the regenerative medicine compan…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
